国家银屑病基金会COVID-19工作组疫情期间银屑病管理指南(第1版)
该指南由国家银屑病基金会(NPF)召集的18名投票委员工作组制定,成员涵盖皮肤病学、风湿病学、流行病学、感染病学和重症医学专家,并辅以非投票成员。工作组以银屑病社区收到的实际问题为临床问题来源,采用Delphi流程形成推荐。最终批准22条推荐意见,所有意见均获推荐,其中9条高度共识、13条中度共识。原文指出许多推荐意见背后的证据质量有限。该指南旨在作为随数据更新而修订的动态文件。
要点
- 工作组批准22条推荐意见,所有意见均获推荐,其中9条高度共识、13条中度共识。
- 推荐意见涵盖银屑病及其治疗如何影响COVID-19风险和结局、疫情期间如何优化医疗照护、患者如何降低SARS-CoV-2感染风险及感染后如何处理。
- 原文指出许多推荐意见背后的证据质量有限。
- 该指南为动态文件,工作组将随数据出现而更新。
- 制定方法为18名投票委员的Delphi流程,临床问题来源于银屑病社区向NPF提出的问题。
研究设计与关键结果
- 工作组由18名投票委员组成,专业涵盖皮肤病学、风湿病学、流行病学、感染病学和重症医学,并辅以研究员和NPF工作人员等非投票成员。
- 临床问题来源于银屑病社区向NPF提出的问题,采用Delphi流程形成推荐。
- 工作组批准22条推荐意见,所有意见均获推荐,其中9条高度共识、13条中度共识。
- 推荐意见涵盖银屑病及其治疗对COVID-19风险和结局的影响、疫情期间医疗照护的优化、患者降低SARS-CoV-2感染风险的措施及感染COVID-19后的处理。
证据类型、等级与局限
- 证据类型:指南(工作组Delphi流程形成的推荐意见)。
- 共识强度:22条推荐意见均获推荐,9条高度共识、13条中度共识。
- 局限:原文指出许多推荐意见背后的证据质量有限。
对床旁实践的改变
- 该指南为疫情期间银屑病患者管理提供推荐意见,涵盖疾病与治疗对COVID-19风险及结局的影响、医疗照护优化、感染预防及感染后处理。
- 原文指出该指南为动态文件,工作组将随数据出现而更新。
指南或共识出处
- 国家银屑病基金会COVID-19工作组疫情期间银屑病管理指南(第1版),制定机构为国家银屑病基金会(NPF),原文未注明发布年份。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic.
STUDY DESIGN: A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and critical care was convened. The TF was supplemented by nonvoting members, which included fellows and National Psoriasis Foundation (NPF) staff. Clinical questions relevant to the psoriatic disease community were informed by questions received by the NPF. A Delphi process was conducted.
RESULTS: The TF approved 22 guidance statements. The average of the votes was within the category of agreement for all statements. All guidance statements proposed were recommended, 9 with high consensus and 13 with moderate consensus.
LIMITATIONS: The evidence behind many guidance statements is limited in quality.
CONCLUSION: These statements provide guidance for the management of patients with psoriatic disease on topics ranging from how the disease and its treatments impact COVID-19 risk and outcome, how medical care can be optimized during the pandemic, what patients should do to lower their risk of getting infected with severe acute respiratory syndrome coronavirus 2 and what they should do if they develop COVID-19. The guidance is intended to be a living document that will be updated by the TF as data emerge.
参考来源
- Gelfand JM, Armstrong AW, Bell S, et al. National Psoriasis Foundation COVID-19 Task Force Guidance for Management of Psoriatic Disease During the Pandemic: Version 1. J Am Acad Dermatol. 2020. PMID: 32891785. doi:10.1016/j.jaad.2020.09.001
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。